Skip to content

Startup & venture capital news

Acta Pharmaceuticals announces USD 24m in total seed financing

Boston company advances an investigational Alzheimer's disease program

By /

LinkedInX
Acta Pharmaceuticals: Acta Pharmaceuticals announces USD 24m in total seed financing
Acta company website; photographer not stated

Acta Pharmaceuticals announced USD 24 million in total seed financing on 15 October 2026. The Boston company is developing therapies for earlier intervention in Alzheimer's disease, building on scientific founder Dr Rudolph Tanzi's research. Its lead candidate, GSM-779690T, is an oral gamma-secretase modulator intended to alter production of amyloid beta proteins. Acta plans a Phase 1 study assessing safety, tolerability and pharmacokinetics in healthy volunteers. Shareholders include Alzheimer's Disease Research Foundation, Dolby Family Ventures and Gamma Bio Investors, but no lead was named. The total seed figure is distinct from historical research support. Clinical safety and efficacy remain unestablished.

Keep reading

More Funding

All stories